In 2023, West Virginia had the highest share of adults (**** percent) who had ever been told by a doctor that they had diabetes. This statistic represents the percentage of adults in the United States who had ever been diagnosed diabetes as of 2023, by state.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

In 2023, the prevalence of diagnosed diabetes in the United States among people aged 18 and over amounted to *** percent. This was an increase from *** percent in the year 2000. How many people in the United States have diabetes? It was estimated that in 2023, almost **** million people in the United States had been diagnosed with diabetes. The number of people living with diabetes has increased over the past few decades, with only **** million people living with diabetes in the year 1980. Diabetes in the United States is more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to ** percent of those aged 40 to 59 years. Leading diabetic states In 2023, the U.S. states with the highest prevalence of diagnosed diabetes were West Virginia, Mississippi, and Louisiana. Just over ** percent of adults in West Virginia had diabetes that year. In Utah, just under ***** percent of adults have been diagnosed with diabetes, the lowest share in the United States.

Population-based county-level estimates for diagnosed (DDP), undiagnosed (UDP), and total diabetes prevalence (TDP) were acquired from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (Evaluation 2017). Prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or hemoglobin A1C (HbA1C) levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (Dwyer-Lindgren, Mackenbach et al. 2016). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or A1C status for each BRFSS respondent (Dwyer-Lindgren, Mackenbach et al. 2016). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict the county-level prevalence of each of the diabetes-related outcomes (Dwyer-Lindgren, Mackenbach et al. 2016). Diagnosed diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis, represented as an age-standardized prevalence percentage. Undiagnosed diabetes was defined as proportion of adults (age 20+ years) who have a high FPG or HbA1C but did not report a previous diagnosis of diabetes. Total diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis and/or had a high FPG/HbA1C. The age-standardized diabetes prevalence (%) was used as the outcome. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, S. Shaikh, D. Lobdell, and R. Sargis. Association between environmental quality and diabetes in the U.S.A.. Journal of Diabetes Investigation. John Wiley & Sons, Inc., Hoboken, NJ, USA, 11(2): 315-324, (2020).

It was estimated that as of 2022 around 24.4 million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the eighth leading cause of death in the United States, accounting for three percent of all deaths.

What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around 53 million men and 44 million women in the United States had prediabetes. However, according to the CDC, around 80 percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are Hawaii, California, and Alaska.

The prevalence of diabetes in the United States As of 2022, around 8.4 percent of adults in the United States had been diagnosed with diabetes, an increase from six percent in the year 2000. Diabetes is much more common among older adults, with almost a quarter of those aged 65 years and older diagnosed with diabetes, compared to just three percent of those aged 18 to 44 years. The states with the highest prevalence of diabetes among adults are Alabama, Mississippi, and West Virginia, while Colorado and Alaska report the lowest rates. In Alabama, around 17 percent of adults have been diagnosed with diabetes.

In 2014, 18.5 percent of adults aged 75 years and older in the United States had diagnosed diabetes. By 2060, prevalence of diabetes in adults aged 75 years and older is projected to be 36 percent. This statistic shows the projected prevalence of diagnosed diabetes in adults in the U.S. by age group for selected years from 2014 to 2060.

This dataset contains information on the total proportion of adults diagnosed with diabetes, collected from the system of health-related telephone surveys, the Behavioral Risk Factor Surveillance System (BRFSS), conducted in more than 400,000 patients, from 50 states in the US, the District of Columbia and three US territories.

U.S. Census, Policy MapCrude percent of adults diagnosed with diabetes in 2019

IntroductionNo study has comprehensively quantified the individual and collective contributions of various risk factors to the growing burden of diabetes in the United States.MethodsThis study aimed to determine the extent to which an increase in the prevalence of diabetes was related to concurrent changes in the distribution of diabetes-related risk factors among US adults (aged 20 years or above and not pregnant). Seven cycles of series of cross-sectional National Health and Nutrition Examination Survey data between 2005–2006 and 2017–2018 were included. The exposures were survey cycles and seven domains of risk factors, including genetic, demographic, social determinants of health, lifestyle, obesity, biological, and psychosocial domains. Using Poisson regressions, percent reduction in the β coefficient (the logarithm used to calculate the prevalence ratio for prevalence of diabetes in 2017–2018 vs. 2005–2006) was computed to assess the individual and collective contribution of the 31 prespecified risk factors and seven domains to the growing burden of diabetes.ResultsOf the 16,091 participants included, the unadjusted prevalence of diabetes increased from 12.2% in 2005–2006 to 17.1% in 2017–2018 [prevalence ratio: 1.40 (95% CI, 1.14–1.72)]. Individually, genetic domain [17.3% (95% CI, 5.4%−40.8%)], demographic domain [41.5% (95% CI, 24.4%−76.8%)], obesity domain [35.3% (95% CI, 15.8%−70.2%)], biological domain [46.2% (95% CI, 21.6%−79.1%)], and psychosocial domain [21.3% (95% CI, 9.5%−40.1%)] were significantly associated with a different percent reduction in β. After adjusting for all seven domains, the percent reduction in β was 97.3% (95% CI, 62.7%−164.8%).ConclusionThe concurrently changing risk factors accounted for the increasing diabetes prevalence. However, the contribution of each risk factor domain varied. Findings may inform planning cost-effective and targeted public health programs for diabetes prevention.

In 2023, it was estimated that almost 21 percent of those aged 65 years and older in the United States had been diagnosed with diabetes. This statistic shows the percentage of U.S. adults aged 65 years and older who had ever been told by a doctor or other health professional they had diabetes from 2019 to 2023.

Multicenter clinical research study aimed at discovering whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in study participants. At the beginning of the DPP, all 3,234 study participants were overweight and had blood glucose levels higher than normal but not high enough for a diagnosis of diabetesa condition called prediabetes. In addition, 45 percent of the participants were from minority groups-African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, or Pacific Islander-at increased risk of developing diabetes. The DPP found that participants who lost a modest amount of weight through dietary changes and increased physical activity sharply reduced their chances of developing diabetes. Taking metformin also reduced risk, although less dramatically. In the DPP, participants from 27 clinical centers around the United States were randomly divided into different treatment groups. The first group, called the lifestyle intervention group, received intensive training in diet, physical activity, and behavior modification. By eating less fat and fewer calories and exercising for a total of 150 minutes a week, they aimed to lose 7 percent of their body weight and maintain that loss. The second group took 850 mg of metformin twice a day. The third group received placebo pills instead of metformin. The metformin and placebo groups also received information about diet and exercise but no intensive motivational counseling. A fourth group was treated with the drug troglitazone (Rezulin), but this part of the study was discontinued after researchers discovered that troglitazone can cause serious liver damage. The participants in this group were followed but not included as one of the intervention groups. In the years since the DPP was completed, further analyses of DPP data continue to yield important insights into the value of lifestyle changes in helping people prevent type 2 diabetes and associated conditions. For example, one analysis confirmed that DPP participants carrying two copies of a gene variant, or mutation, that significantly increased their risk of developing diabetes benefited from lifestyle changes as much as or more than those without the gene variant. Another analysis found that weight loss was the main predictor of reduced risk for developing diabetes in DPP lifestyle intervention group participants. The authors concluded that diabetes risk reduction efforts should focus on weight loss, which is helped by increased exercise.

In 1999-2000, it was estimated that around 3.8 percent of adults in the United States aged 20 years and older had undiagnosed diabetes. In August 2021-August 2023, this rate was 4.2 percent. This statistic shows the percentage of adults in the United States with undiagnosed diabetes from 1999 to August 2023.

Inadequately Controlled Type-II Diabetes Treatment Market Outlook

According to our latest research, the global inadequately controlled Type-II diabetes treatment market size reached USD 27.4 billion in 2024. The market is experiencing robust growth, with a recorded CAGR of 7.1% from 2025 to 2033. By the end of 2033, the market is forecasted to attain a size of USD 51.2 billion. This growth is primarily driven by the rising prevalence of Type-II diabetes worldwide, increasing awareness about the complications associated with poorly managed diabetes, and the continuous innovation in pharmacological therapies aimed at improving glycemic control.

One of the major growth factors propelling the inadequately controlled Type-II diabetes treatment market is the escalating global burden of diabetes, particularly in developing nations. The International Diabetes Federation estimates that over 537 million adults are currently living with diabetes, and a significant proportion of these patients are unable to achieve optimal glycemic control despite existing therapeutic regimens. This unmet clinical need is fueling the demand for advanced treatment options, including novel drug classes and combination therapies. Additionally, the growing adoption of personalized medicine and precision therapies is further enhancing treatment efficacy, thereby attracting substantial investments from both public and private sectors.

Another key driver is the advancement in drug delivery technologies and the introduction of next-generation therapeutics, such as GLP-1 receptor agonists and SGLT2 inhibitors. These therapies have demonstrated superior efficacy in managing blood glucose levels and reducing the risk of diabetes-related complications, especially for patients who have not responded adequately to traditional treatments like sulfonylureas and thiazolidinediones. The increased focus on patient-centric care and the integration of digital health solutions for continuous glucose monitoring are also contributing to improved disease management and better patient outcomes, which in turn is accelerating market growth.

Moreover, favorable reimbursement policies and supportive government initiatives aimed at improving diabetes care infrastructure are playing a pivotal role in market expansion. Several countries have launched national diabetes control programs and are investing in public health campaigns to raise awareness about the importance of timely diagnosis and effective disease management. These initiatives are complemented by the efforts of pharmaceutical companies to expand their product portfolios and strengthen their distribution networks, particularly in emerging markets where the prevalence of inadequately controlled Type-II diabetes is rising at an alarming rate.

From a regional perspective, North America continues to dominate the inadequately controlled Type-II diabetes treatment market, accounting for the largest revenue share in 2024. This can be attributed to the high prevalence of diabetes, early adoption of innovative therapies, and the presence of leading pharmaceutical companies in the region. However, Asia Pacific is expected to witness the fastest growth during the forecast period, driven by rapid urbanization, changing lifestyles, and increasing healthcare expenditure. Europe also holds a significant market share, supported by strong healthcare infrastructure and ongoing research and development activities. The Middle East & Africa and Latin America are emerging as promising markets, with increasing government focus on healthcare access and rising awareness about diabetes management.

Drug Class Analysis

The inadequately controlled Type-II diabetes treatment market is segmented by drug class into insulin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, and others. Among these, insulin remains the cornerstone of therapy for patients who fail to achieve glycemic targets with oral agents. In 2024, insulin accounted for the largest market share, owing to its proven efficacy in lowering blood glucose l

Surveys in which U.S. adults report their current weight have shown that the share of those reporting they weigh 200 pounds or more has increased over the past few decades. In 2024, around 28 percent of respondents reported their weight as 200 pounds or more, compared to 15 percent in 1990. However, the same surveys show the share of respondents who report they are overweight has decreased compared to figures from 1990. What percentage of the U.S. population is obese? Obesity is an increasing problem in the United States that is expected to become worse in the coming decades. As of 2023, around one third of adults in the United States were considered obese. Obesity is slightly more prevalent among women in the United States, and rates of obesity differ greatly by region and state. For example, in West Virginia, around 41 percent of adults are obese, compared to 25 percent in Colorado. However, although Colorado is the state with the lowest prevalence of obesity among adults, a quarter of the adult population being obese is still shockingly high. The health impacts of being obese Obesity increases the risk of developing a number of health conditions including high blood pressure, heart disease, type 2 diabetes, and certain types of cancer. It is no coincidence that the states with the highest rates of hypertension are also among the states with the highest prevalence of obesity. West Virginia currently has the third highest rate of hypertension in the U.S. with 45 percent of adults with the condition. It is also no coincidence that as rates of obesity in the United States have increased so have rates of diabetes. As of 2022, around 8.4 percent of adults in the United States had been diagnosed with diabetes, compared to six percent in the year 2000. Obesity can be prevented through a healthy diet and regular exercise, which also increases overall health and longevity.

From 2017 to March 2020, the prevalence of diabetes among adult men with obesity in the United States was around ** percent. This statistic shows the prevalence of diabetes in the U.S. from 2017 to March 2020, by age and weight status.

In 1999-2000, it was estimated that around 9.7 percent of adults in the United States aged 20 years and older had either diagnosed or undiagnosed diabetes. By August 2021-August 2023, this had risen to around 14.3 percent. This statistic shows the percentage of adults in the United States with diabetes from 1999 to August 2023.

In 2024, around 16 percent of adults between the ages of 20 and 79 had diabetes in Turkey. Other selected countries with a high prevalence of diabetes that year included Mexico, the United States, and Portugal. Diabetes is a metabolic disease that causes high blood sugar levels. Diabetes worldwide In 2024, an estimated 11 percent of the global adult population had diabetes. In concrete numbers, there were about 589 million diabetic adults (20-79 years) worldwide in 2024, and this total is predicted to grow to approximately 852.5 million by the year 2050. Spending per patient The country that spent the most on patients with diabetes in 2024 was Switzerland. At that time, providing for a diabetic patient in Switzerland cost an average of over 12 thousand U.S. dollars. The United States stood in second place, spending about 10,500 U.S. dollars per patient. In the same year, the ten countries by lowest average spending per person with diabetes were all African and Asian countries. Bangladesh had the lowest annual diabetes-related health expenditures per person, with just 74 U.S. dollars.

From 2013 to 2021, it was estimated that around 11 percent of adults in the United States had been diagnosed with diabetes. In comparison, just over four percent had been diagnosed with myocardial infarction. This statistic depicts the prevalence of select cardiometabolic diseases among adults in the United States from 2013 to 2021.

Around ** percent of the global adult population suffered from diabetes in 2024 - by the year 2050 this number is expected to rise to ** percent. Diabetes, or diabetes mellitus, refers to a group of metabolic disorders that result in chronic high blood sugar levels. Diabetes can lead to serious health complications, such as cardiovascular disease, chronic kidney disease, and stroke, and is now among the top ten leading causes of death worldwide. Prevalence Diabetes is a global problem affecting many countries. China currently has the largest number of diabetics worldwide, with some *** million people suffering from the disease. However, the highest prevalence of diabetes is found in Pakistan, followed by the Marshall Islands and Kuwait. Rates of diabetes have increased in many countries in recent years, as have rates of obesity, one of the leading risk factors for the disease. Outlook It is predicted that diabetes will continue to be a problem in the future. Africa is expected to see a *** percent increase in the number of diabetics in the region from 2024 to 2050, while North America and the Caribbean are expected to see an increase of ** percent. In 2050, China is predicted to be the country with the highest number of diabetics worldwide, with the United States accounting for the fourth-highest number.

In the period August 2021 to August 2023, around 19.6 percent of adults in the United States with a high school degree, GED, or less suffered from diabetes. This statistic shows the prevalence of diagnosed and undiagnosed diabetes among adults in the U.S. from August 2021 to August 2023, by education.